Core Insights - BioNxt Solutions Inc. has received a "Readiness to Grant" notification from the Eurasian Patent Organization for its patent application related to sublingual delivery of anticancer drugs targeting autoimmune neurodegenerative diseases [1] - The patent family opens up various proprietary product development and commercialization opportunities for the company [1] - BioNxt's lead product, BNT23001, is a sublingual thin-film formulation of Cladribine aimed at treating multiple sclerosis [1]